ESMO 2024 preview – Summit and BioNTech battle again
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
EHA 2024 preview – Novartis doubles up
The conference’s abstract drop features ASC4First in its plenary session.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Janux gives conditionally acting therapeutics hope
Early activity of JANX007 in prostate cancer sees Janux stock gain 190%.
Deal analysis part one – the bad
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
